Covaxin stock 'very low'; may hold up hit vaccinations: Bengal official

The state was supposed to get 75 lakh of vaccine doses this month and received 54 lakh till Friday.

Covaxin, Covishield, serum institute of india, bharat biotech, vaccine, vaccination, coronavirus, covid
Press Trust of India Kolkata
2 min read Last Updated : Jul 25 2021 | 6:27 AM IST

A "very low" stock of Covaxin and a meagre supply of the vaccines are going to badly affect the ongoing inoculation process in West Bengal, a senior health department official said on Saturday.

The state was supposed to get 75 lakh of vaccine doses this month and received 54 lakh till Friday, he said.

"The Covaxin stock in our state is very low. We have only one lakh and some small quantity in the hands of the districts. We were supposed to receive two tranches of a total of 2.55 lakh Covaxin which were not delivered as per schedule," the official said.

Till Saturday, West Bengal has received a total of 2.36 crore vaccine doses from the central government and procured at least 17.74 lakh doses, he said.

The state has vaccinated over 2.75 crore people so far and out of them, 81.9 lakh got the second dose, he said.

According to the official, the state has currently the infrastructure to administer more than 1.5 crore doses per month.

"The only constraint is getting an adequate quantity of vaccine on time," he said.

West Bengal Chief Minister Mamata Banerjee has urged the central government to allot at least three crore vaccine doses to the state.

Meanwhile, on Saturday, the Covid-19 toll in West Bengal rose to 18,604 with eight more deaths while the tally went up by another 730 new cases to reach 15,22,833, the health department said in a bulletin.

In the last 24 hours, 920 recoveries were registered in the state, which improved the discharge rate to 98.03 per cent.

Till Saturday, 14,92,878 people have recovered from the disease and the state currently has 11,891 active cases.

In the last 24 hours, 52,188 samples have been tested for Covid-19 taking the total number of such clinical examinations to 1,54,28,549, the bulletin added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Jul 25 2021 | 5:39 AM IST

Next Story